BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

ALAMEDA, Calif.--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;$BTXlt;/agt; lt;a href="" target="_blank"gt;#AMDlt;/agt;--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, reported financial and operating results for the fourth quarter and full year ended December 31, 2018. BioTime management will host a conference call and webcast today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to provide a business update. “BioTime has been moving rapidly towards building a pioneering cell therapy company through strategi

Full Story →